Enzon Pharmaceuticals (OTCMKTS:ENZN – Get Free Report) issued its quarterly earnings results on Monday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.
Enzon Pharmaceuticals Stock Performance
ENZN stock opened at $0.06 on Wednesday. The firm has a market cap of $4.65 million, a P/E ratio of -1.25 and a beta of 0.20. The stock’s 50 day moving average price is $0.06 and its 200 day moving average price is $0.06. Enzon Pharmaceuticals has a 1 year low of $0.03 and a 1 year high of $0.13.
Enzon Pharmaceuticals Company Profile
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Read More
- Five stocks we like better than Enzon Pharmaceuticals
- New Copper-Rich “Kraken” Zone Discovered
- Elon Warns “America Is Broke”. Trump’s Plan Inside.
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
